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Abstract 
Background: COVID‑19 can course with respiratory and extrapulmonary disease. SARS‑CoV‑2 RNA is detected in res‑
piratory samples but also in blood, stool and urine. Severe COVID‑19 is characterized by a dysregulated host response 
to this virus. We studied whether viral RNAemia or viral RNA load in plasma is associated with severe COVID‑19 and 
also to this dysregulated response.
Methods: A total of 250 patients with COVID‑19 were recruited (50 outpatients, 100 hospitalized ward patients and 
100 critically ill). Viral RNA detection and quantification in plasma was performed using droplet digital PCR, targeting 
the N1 and N2 regions of the SARS‑CoV‑2 nucleoprotein gene. The association between SARS‑CoV‑2 RNAemia and 
viral RNA load in plasma with severity was evaluated by multivariate logistic regression. Correlations between viral 
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Background
With well over 43 million cases and 1.56212 deaths glob-
ally, Coronavirus disease 2019 (COVID-19) has become 
the top economic and health priority worldwide [1]. 
Among hospitalized patients, around 10–20% are admit-
ted to the intensive care unit (ICU), 3–10% require intu-
bation and 2–5% die [2]. SARS-CoV-2 RNA is commonly 
detected in nasopharyngeal swabs; however, viral RNA 
can be found in sputum, lung samples, peripheral blood, 
serum, stool samples and to a limited extent urine [3–6]. 
While the lungs are most often affected, severe COVID-
19 also induces inflammatory cell infiltration, haemor-
rhage and degeneration or necrosis in extra-pulmonary 
organs (spleen, lymph nodes, kidney, liver, central nerv-
ous system) [7, 8]. Patients with severe COVID-19 show 
signatures of dysregulated response to infection, with 
immunological alterations involving moderate elevation 
of some cytokines and chemokines such as IL-6, IL-10 or 
CXCL10, deep lymphopenia with neutrophilia, systemic 
inflammation (elevation of C-reactive protein, ferritin), 
endothelial dysfunction, coagulation hyper-activation 
(D-dimers) and tissue damage (LDH) [9–14].
Our hypothesis is that systemic distribution of the virus 
or viral components could be associated with the sever-
ity of COVID-19, and in turn to a number of parameters 
indicating the presence of a dysregulated response to the 
infection.
While the SARS-CoV-2 virus has been reported to be 
difficult to culture from blood [4], PCR-based methods 
are able to detect and quantify the presence of genomic 
material of the virus in serum or plasma, representing an 
useful approach to evaluate the impact of the extrapul-
monary dissemination of viral material on disease 
severity and also on the host response to the infection [5, 
15]. An excellent approach for achieving absolute quanti-
fication of viral RNA load is droplet digital PCR (ddPCR). 
ddPCR is a next-generation PCR method, which offers 
absolute quantification with no need of standard curve 
and greater precision and reproducibility than currently 
available qRT-PCR methods, as revised elsewhere [16].
We employed here ddPCR to detect and quantify viral 
RNA in plasma from COVID-19 patients discharged 
from the emergency room with mild severity, patients 
admitted to the ward with moderate severity and criti-
cally ill patients. Our objectives in this study were: (1) to 
evaluate if there is an association between SARS-CoV-2 
RNAemia and viral RNA load with moderate disease; 
(2) to evaluate if there is an association between SARS-
CoV-2 RNAemia and viral RNA load with critical illness; 
and (3) to evaluate the correlations between SARS-CoV-2 




A total of 250 adult patients with a positive naso-
pharyngeal swab polymerase chain reaction (PCR) test 
for SARS-CoV-2 performed at participating hospitals 
were recruited during the first pandemic wave in Spain 
from March 16th to the 15th of April 2020. The patients 
recruited were of three different categories. The first cor-
responded to patients examined at an emergency room 
and discharged within the first 24  h (outpatients group, 
n = 50). The second group were patients hospitalized to 
pneumology, infectious diseases or internal medicine 
wards (wards group, n = 100). Patients who required 
RNA load and biomarkers evidencing dysregulation of host response were evaluated by calculating the Spearman 
correlation coefficients.
Results: The frequency of viral RNAemia was higher in the critically ill patients (78%) compared to ward patients 
(27%) and outpatients (2%) (p < 0.001). Critical patients had higher viral RNA loads in plasma than non‑critically ill 
patients, with non‑survivors showing the highest values. When outpatients and ward patients were compared, viral 
RNAemia did not show significant associations in the multivariate analysis. In contrast, when ward patients were 
compared with ICU patients, both viral RNAemia and viral RNA load in plasma were associated with critical illness (OR 
[CI 95%], p): RNAemia (3.92 [1.183–12.968], 0.025), viral RNA load (N1) (1.962 [1.244–3.096], 0.004); viral RNA load (N2) 
(2.229 [1.382–3.595], 0.001). Viral RNA load in plasma correlated with higher levels of chemokines (CXCL10, CCL2), 
biomarkers indicative of a systemic inflammatory response (IL‑6, CRP, ferritin), activation of NK cells (IL‑15), endothelial 
dysfunction (VCAM‑1, angiopoietin‑2, ICAM‑1), coagulation activation (D‑Dimer and INR), tissue damage (LDH, GPT), 
neutrophil response (neutrophils counts, myeloperoxidase, GM‑CSF) and immunodepression (PD‑L1, IL‑10, lymphope‑
nia and monocytopenia).
Conclusions: SARS‑CoV‑2 RNAemia and viral RNA load in plasma are associated with critical illness in COVID‑19. Viral 
RNA load in plasma correlates with key signatures of dysregulated host responses, suggesting a major role of uncon‑
trolled viral replication in the pathogenesis of this disease.
Keywords: SARS‑CoV‑2, Cytokine, Sepsis, COVID‑19, Plasma, Rnaemia, Viral RNA load, ICU
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critical care or died during hospitalization were excluded 
from this group, in order to have a group of clear mod-
erate severity. The third group corresponded to patients 
admitted to the ICU (n = 100). Patient`s recruited by 
participating hospital are detailed in the Additional 
file  1. Twenty healthy blood donors were included as 
controls. These controls were recruited during the pan-
demics, in parallel to the SARS-CoV-2 infected patients, 
and were negative for SARS-CoV-2 IgG. This study was 
registered at Clinicaltrials.gov with the identification 
NCT04457505.
Blood samples
Plasma from blood collected in EDTA tubes samples was 
obtained from the three groups of patients in the first 
24 h following admission to the emergency room, to the 
ward, or to the ICU, at a median collection day since dis-
ease onset of 7, 8 and 10, respectively, and also from 20 
blood donors (10 men and 10 women).
Biomarker profiling
A panel of biomarkers was profiled by using the Ella-
SimplePlex™ immunoassay (San Jose, California, USA), 
informing of the following biological functions poten-
tially altered in severe COVID-19, based in the available 
evidence on COVID-19 physiopathology [13] [17] and 
also in our previous experience on emerging infections 
and sepsis [18–21]: neutrophil degranulation: Lipoca-
lin-2/NGAL, myeloperoxidase; endothelial dysfunction: 
ICAM-1, VCAM-1/CD106, angiopoietin-2; T cell sur-
vival and function: IL-7, Granzyme B; immunosuppres-
sion: IL-1ra, B7-H1/PD-L1, IL-10; chemotaxis: CXCL10/
IP10, CCL2; Th1 response: interleukin 1 beta, IFN-γ, IL-
12p70, IL-15, TNF-α, IL-2; Th2 response: IL-4, IL-10; 
Th17 response: IL-6, IL-17A; granulocyte mobilization 
/ activation: G-CSF, GM-CSF; coagulation activation: 
D-Dimer; acute phase reactants: ferritin (C-reactive pro-
tein and LDH were profiled in each participant hospital 
by their central laboratories).
Detection and quantification of SARS‑CoV‑2 RNA in plasma
RNA was extracted from 100  µl of plasma using an 
automated system, eMAG® from bioMérieux® (Marcy 
l’Etoile, France). Detection and quantification of SARS-
CoV-2 RNA was performed in five µl of the eluted solu-
tion using the Bio-Rad SARS-CoV-2 ddPCR kit according 
to manufacturer’s specifications on a QX-200 droplet 
digital PCR platform from the same provider. This PCR 
targets the N1 and N2 regions of the viral nucleoprotein 
gene and also the human ribonuclease (RNase) P gene 
using the primers and probes sets detailed in the CDC 
2019 Novel Coronavirus (2019-nCoV) Real-Time RT-
PCR Diagnostic Panel [22]. Samples were considered 
positive for SARS-CoV-2 when N1 and/or N2 presented 
values ≥ 0.1 copies/µL in a given reaction. RNase P gene 
was considered positive when it presented values ≥ 0.2 
copies/µL, following manufacturer`s indications. The 
test was only considered valid when RNase P gene was 
positive. Final results were given in copies of cDNA / mL 
of plasma. IgG specific for the nucleocapsid protein of 
SARS–CoV-2 was detected in 150 µl of plasma using the 
Abbott Architect SARS-CoV-2 IgG Assay (Illinois, USA). 
Viral RNA and SARS-CoV-2 IgG were profiled in the 
same plasma sample.
Statistical analysis
For the demographic and clinical characteristics of the 
patients, the differences between groups were assessed 
using the Chi-square test / Fisher’s exact test where 
appropriated for categorical variables. Differences for 
continuous variables were assessed by using the Kruskal–
Wallis test with post hoc tests adjusting for multiple 
comparisons. Multivariate logistic regression analysis 
was employed to evaluate the association between viral 
RNAemia and viral RNA load in plasma with severity, 
in the comparisons [outpatients vs ward patients] and 
[ward patients vs ICU patients]. Variables showing sig-
nificant differences between groups in each comparison 
in the Kruskal–Wallis test were further introduced in 
the multivariate analysis as adjusting variables. The list 
of variables considered as potential adjusting variables 
were [Age (years)], [Sex (male)], [Alcoholism], [Smoker], 
[Drug abuse], [Cardiac disease], [Chronic vascular dis-
ease], [COPD], [Asthma], [Obesity], [Hypertension], 
[Dyslipidemia], [Chronic renal disease], [Chronic hepatic 
disease], [Neurological disease], [HIV], [Autoimmune 
disease], [Chronic inflammatory bowel disease], [Type 1 
diabetes], [Type 2 diabetes], [Cancer], [Invasive mechani-
cal ventilation], [Non-invasive mechanical ventilation], 
[SARS-CoV-2 IgG], [Temperature (ºC)], [Systolic pres-
sure (mmHg)], [Oxygen saturation (%)], [Bilateral pulmo-
nary infiltrate], [Glucose (mg/dl)], [Creatinine (mg/dl)], 
[Na (mEq/L)], [K (mEq/L)], [Platelets (cell × 103 / µl)], 
[INR], [D Dimer (pg/ml)], [LDH (UI/L)], [GPT (UI/L)], 
[Ferritin (pg/ml)], [CRP (mg/dl)], [Haematocrit (%)], 
[Lymphocytes (cells/mm3)], [Neutrophils (cells/mm3)], 
[Monocytes (cells/mm3)]. Multivariate logistic regres-
sion analysis was performed using the “Enter” method, 
but also the backward stepwise selection method (Like-
lihood Ratio) was employed in each case to confirm the 
association between viral RNAemia and viral RNA load 
in plasma with disease severity (pin < 0.05, pout < 0.10), 
not forcing entry of these variables in the model. Cor-
relation analysis was performed using the Spearman test 
applying the Bonferroni correction of the p value. Vari-
ables evaluated for correlation with viral RNA load were: 
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[Temperature (ºC)], [Systolic pressure (mmHg)], [Oxygen 
saturation (%)], [Lymphocytes (cells/mm3)], [Neutrophils 
(cells/mm3)], [Monocytes (cells/mm3)], [Creatinine (mg/
dl)], [LDH (UI/L)], [GPT (UI/L)], [Platelets (cell × 103 / 
µl)], [INR], [CRP (mg/dl)], and all the biomarkers ana-
lysed by Ella-SimplePlex. Statistical analysis was per-
formed with IBM SPSS® version 20 (IBM, Armonk, New 
York, USA).
Results
Clinical characteristics of the patients (Table 1)
Patients requiring hospitalization (either general ward or 
ICU) were older than those patients discharged to their 
home from the ER. Critically ill patients were more fre-
quently male than those in the other groups. Comor-
bidities of obesity, hypertension, dyslipidemia and type 2 
diabetes were more commonly found in patients requir-
ing hospitalization, with no significant differences found 
in the comorbidities profile between critically ill and non-
critically ill hospitalized patients. Fourteen per cent of the 
patients in clinical wards required non-invasive mechani-
cal ventilation, while 96% of the patients admitted to the 
ICU required invasive mechanical ventilation. Critically 
ill patients had increased glucose levels, along with higher 
concentration of neutrophils in blood, increased levels 
of ferritin and C-reactive protein (denoting activation of 
the systemic inflammatory response). Increased levels of 
INR and D-dimers (reflecting activation of the coagula-
tion system), as well as LDH and GPT, which levels raise 
as consequence of tissue and liver damage, were also 
observed in critically ill patients. Patients admitted to the 
ICU also showed a lower haematocrit, pronounced lym-
phopenia and lower monocyte counts at admission. ICU 
patients stayed longer in the hospital than ward patients, 
with 49% having a fatal outcome.
Viral RNAemia, viral RNA load in plasma and specific 
SARS‑Cov‑2 IgG in the three groups of patients
As depicted in Table  1, the frequency of the detection 
of SARS-CoV-2 viral RNA (RNAemia) was significantly 
higher in the critically ill patients (78%) compared to 
ward patients (27%) and outpatients (2%) (p < 0.001). Sim-
ilarly, the group of critically patients showed higher viral 
RNA loads in plasma than either ward or outpatients 
(p < 0.001) (Table  1 and Fig.  1). Non-survivors showed 
the highest concentrations of viral RNA in plasma: viral 
RNA load (N1 region) in ICU non-survivors: 1587 copies 
/ ml [10248]; viral RNA load (N1 region) in ICU survi-
vors 574 copies / mL [1872] (results expressed as median 
[interquartile rank]); viral RNA load (N2 region) in ICU 
non-survivors: 2798 copies / ml [12012]; viral RNA load 
(N2 region) in ICU survivors 523 copies / mL [1478]. 
Patients admitted to the wards showed a significant 
higher frequency of viral RNAemia than outpatients, but 
viral RNA loads were not significantly different with the 
latter group (Table  1 and Fig.  1). Critically ill patients 
also had a higher frequency of specific SARS-CoV-2 IgG 
responses than the other groups (70% in ICU compared 
to 52% and 49% in the outpatients and ward groups, 
p < 0.05, Table  1). No significant differences were found 
between the group of outpatients and those admitted to 
the ward. The prevalence of viral RNAemia did not differ 
between those patients testing positive and those testing 
negative for SARS-CoV-2 IgG (43.8% and 40.4%, respec-
tively, p = 0.586), who in addition showed no differences 
in viral RNA load (data not shown). Patients with viral 
RNAemia showed no differences in the days since onset 
of symptoms compared to those with no viral RNAemia 
(8.0 days [6.0]; 8.0 days [7.2], p = 0.965). In contrast, sam-
ples from patients with SARS-CoV-2 IgG were collected 
later since disease onset that those without SARS-CoV-2 
IgG (10.0 days [7]; 7.0 days [6.0], p = 0.003).
Multivariate analysis to evaluate the association 
between viral RNAemia and viral RNA load in plasma 
with moderate disease and critical illness
While the proportion of patients with viral RNAemia was 
higher in the wards group compared to the outpatients’ 
group (Table  1), the multivariate analysis did not show 
a significant association between the presence of viral 
RNAemia and being hospitalized at the ward, with none 
of the both methods employed (Additional files 2 and 3). 
In contrast, when the ward group was compared with 
critically ill patients, a significant direct association was 
found between viral RNAemia and viral RNA load with 
critical illness, using the “Enter” method (Table  2) but 
also the backward stepwise selection method (Additional 
file 4).
Correlations between viral RNA load in plasma 
and biological responses to SARS‑CoV‑2 infection
viral RNA load in plasma (targeting either the N1 and 
the N2 regions) showed the strongest direct correlations 
with plasma levels of CXCL10, LDH, IL-10, IL-6, IL-15, 
myeloperoxidase and CCL-2 (MCP-1) and inverse cor-
relations with lymphocytes, monocytes and O2 satura-
tion (Fig.  2). These were the parameters whose levels 
varied the most in critically patients compared with 
ward and outpatient groups (Figs.  3, 4 and Additional 
file  5). CXCL10 was the most accurate identifier of 
viral RNAemia in plasma (area under the curve (AUC), 
[CI95%], p) = 0.85 [0.80 – 0.89), < 0.001), and IL-15 was 
the cytokine which most accurately differentiated clini-
cal ward patients from ICU patients (AUC: 0.82 [0.76 
– 0.88], < 0.001). Plasma viral RNA load also showed 
significant direct correlations with levels of VCAM-1, 
Page 5 of 13Bermejo‑Martin et al. Crit Care          (2020) 24:691  
Table 1 Clinical characteristics of the patients






Characteristics Age [years, median (IQR)] 48.50 [19] 64 [20] 66 [19]  < 0.001  < 0.001 n.s
Male [%, (n)] 46 (23) 50 (50) 64 (64) n.s 0.035 0.046
Comorbidities, [% (n)] Alcoholism 2 (1) 0 (0) 1 (1) n.s n.s n.s
Smoking 4 (2) 5 (5) 6 (6) n.s n.s n.s
Drug abuse 2 (1) 0 (0) 0 (0) n.s n.s n.a
Cardiac disease 4 (2) 13 (13) 9 (9) n.s n.s n.s
Chronic vascular disease 2 (1) 2 (2) 5 (5) n.s n.s n.s
COPD 2 (1) 2 (2) 3 (3) n.s n.s n.s
Asthma 8 (4) 6 (6) 2 (2) n.s n.s n.s
Obesity 4 (2) 26 (26) 26 (26) 0.001 0.001 n.s
Hypertension 24 (12) 44 (44) 45 (45) 0.017 0.012 n.s
Dyslipidemia 16 (8) 41 (41) 34 (34) 0.002 0.021 n.s
Chronic renal disease 2 (1) 3 (3) 3 (3) n.s n.s n.s
Chronic hepatic disease 2 (1) 0 (0) 3 (3) n.s n.s n.s
Neurological disease 0 (0) 6 (6) 3 (3) n.s n.s n.s
HIV 0 (0) 0 (0) 1 (1) n.a n.s n.s
Autoimmune disease 2 (1) 1 (1) 1 (1) n.s n.s n.s
Chronic inflammatory bowel 
disease
0 (0) 2 (2) 1 (1) n.s n.s n.s
Type 1 diabetes 0 (0) 0 (0) 3 (3) n.a n.s n.s
Type 2 diabetes 0 (0) 23 (23) 22 (22)  < 0.001  < 0.001 n.s
Cancer 6 (3) 2 (2) 1 (1) n.s n.s n.s
Treatment during hospitalization, 
[% (n)]
Invasive mechanical ventilation 0 (0) 0 (0) 96 (96) n.a  < 0.001  < 0.001
Non‑invasive mechanical ventila‑
tion
0 (0) 14 (14) 34 (34) 0.004  < 0.001 0.002
Hydroxychloroquine 77.6 (38) 89 (89) 99 (99) n.s  < 0.001 0.003
Chloroquine 4.1 (2) 7 (7) 0 (0) n.s 0.042 0.007
Corticoids 6.7 (3) 29 (29) 85 (85) 0.002  < 0.001  < 0.001
Azithromycin 15.9 (7) 84 (84) 84 (84)  < 0.001  < 0.001 n.s
Remdesivir 0 (0) 1 (1) 9 (9) n.s 0.029 0.009
Tocilizumab 0 (0) 13 (13) 33 (33) 0.008  < 0.001 0.001
Lopinavir/ritonavir 74 (37) 35 (35) 96 (96)  < 0.001  < 0.001  < 0.001
Beta Interferon 0 (0) 0 (0) 55 (55) n.a  < 0.001  < 0.001
Time course and outcome Hospital stay [days, median, (IQR)] – 9 (6) 24 (19) n.a n.a  < 0.001
Viral RNAemia
[% (n)]
2 (1) 27 (27) 78 (78)  < 0.001  < 0.001  < 0.001
Viral RNA load in plasma (N1)
(copies / mL, median, (IQR))
0 (0) 0 (91) 829 (4444) n.s  < 0.001  < 0.001
Viral RNA load in plasma (N2)
(copies / mL, median, (IQR))
0 (0) 0 (93) 836 (4939) n.s  < 0.001  < 0.001
SARS‑CoV‑2 IgG, [% (n)] 52 (26) 49 (49) 70 (70) n.s 0.030 0.002
Hospital mortality, [% (n)] 0 (0) 0 (0) 49(49) n.a  < 0.001  < 0.001
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PDL-1, GM-CSF, G-CSF, neutrophil counts, IL-1ra, CRP, 
INR, D-dimer, TFNα, angiopoietin-2, GPT, ICAM-1, 
IL-7 and ferritin (Fig.  2), with most of these mediators 
showing the highest variations in the critically ill patients 
(Figs. 3, 4 and Additional file 5).
Discussion
Our study demonstrates that the presence of SARS-
CoV-2-RNA in plasma is associated with critical illness 
in COVID-19 patients, with the strength of associa-
tion being the highest in those patients with the high-
est viral RNA loads. This association was independent 
of other factors also related to disease severity. More-
over, those critically ill patients who died presented 
with higher viral RNA loads in plasma than those who 
survived. SARS-CoV-2 viral RNA was detected in the 
plasma of the vast majority of those COVID-19 patients 
admitted to the ICU (78%). As far as we know, our 
study is the largest one to date using ddPCR to quan-
tify SARS-CoV-2 RNA load in plasma from COVID-19 
patients, and the only one with a multicentric design. 
Our results are in consonance with those from Veyer 
et  al., who, in a pilot study using this technology, 
found higher viral RNA loads and a prevalence of RNA 
Continuous variables are represented as [median, (interquartile range, IQR)]; categorical variables are represented as [%, (n)].; INR, International Normalized Ratio; n.s., 
not significant; n.a., not applicable. COPD (Chronic obstructive pulmonary disease), HIV (Human Immunodeficiency Virus), INR (International Normalized Ratio), LDH 
(Lactic Acid Dehydrogenase), GPT (glutamic‑pyruvate transaminase); CRP (C‑reactive protein), WBC (white blood cell)
Table 1 (continued)






Measurements at diagnosis Temperature (ºC) [median (IQR)] 36.50 (1.0) 36.80 (1.4) 37.00 (1.4) – – –
Systolic pressure (mmHg)
[median (IQR)]
120 (29) 126 (25) 120 (26) n.s n.s 0.001
Oxygen saturation (%) [median 
(IQR)]
96 (3) 94 (5) 92 (6) 0.002  < 0.001 0.002
Pulmonary infiltrate [% (n)] 72 (36) 93 (93) 100 (100)  < 0.001  < 0.001 0.007
Bilateral pulmonary infiltrate [% (n)] 26 (13) 67 (67) 93 (93)  < 0.001  < 0.001  < 0.001
Glucose (mg/dl) [median (IQR)] 99.5 (22) 112 (31) 160.50 (83)  < 0.001  < 0.001  < 0.001
Creatinine (mg/dl) [median (IQR)] 0.84 (0.18) 0.91 (0.33) 0.88 (0.57) – – –
Na (mEq/L) [median (IQR)] 138 (4) 138 (5) 138.50 (7) – – –
K (mEq/L) [median (IQR)] 3.90 (0.50) 4.10 (0.68) 3.95 (0.90) – – –
Platelets (cell × 10 3 / µl) [median 
(IQR)]
223 [97] 207 [113] 204 [126] – – –
INR [median (IQR)] 1.04 (0.10) 1.11 (0.13) 1.22 (0.22) 0.004  < 0.001  < 0.001






 < 0.001  < 0.001  < 0.001
LDH (UI/L) [median (IQR)] 214 (73) 278 (138) 496 (285) 0.002  < 0.001  < 0.001
GPT (UI/L) [median (IQR)] 27 (43) 29 (29) 44 (44.50) n.s 0.021 0.001






n.s  < 0.001 0.002
CRP (mg/dl) [median (IQR)] 1.40 (3.50) 40.90 (89.18) 91 (182.10)  < 0.001  < 0.001 0.031
Haematocrit (%) [median (IQR)] 43.15 (4.72) 42.50 (6.50) 38.15 (6.48) n.s  < 0.001  < 0.001
WBC (cells/mm3) [median (IQR)] 6450 (2815) 7005 (4115) 9145 (6613) n.s  < 0.001 0.006
Lymphocytes (cells/mm3)
[median (IQR)]
1400 (805) 1000 (433) 540 (445) 0.006  < 0.001  < 0.001
Neutrophils (cells/mm3)
[median (IQR)]
4260 (2625) 5250 (3918) 8300 (5880) n.s  < 0.001  < 0.001
Monocytes (cells/mm3)
[median (IQR)]
500 (300) 400 (300) 300 (280) n.s  < 0.001  < 0.001
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viremia of 88% in twenty six COVID-19 patients who 
were critically ill [16]. The results are also in agree-
ment with those of Hagman et al., who, using standard 
RT-PCR technology, found that the presence of SARS-
CoV-2 RNA in serum at hospital admission was associ-
ated with a seven-fold increased risk of critical disease 
and an eight-fold increased risk of death in a cohort of 
167 patients hospitalized for COVID-19 [23].
Although our study did not determine if the pres-
ence of viral RNA in plasma reflects the presence of live 
virus in peripheral blood, the association found between 
the presence and concentration of viral RNA in plasma 
Fig. 1 Viral RNA load in plasma, targeting the N1 region (left) and the N2 region (right), in the three groups of patients. Results are provided as 
copies of cDNA per mL of plasma
Table 2 Multivariate logistic regression analysis comparing wards patients against critically ill patients (Enter method)
The association between viral RNAemia or viral RNA load targeting the N1 region, or viral RNA load targeting the N2 region with critical illness was evaluated adjusting 
by major confounding factors
OR [CI95%] p OR [CI95%] p OR [CI95%] p
Sex (male) 2.055 [0.656–6.432 0.216 1.647 [0.508–5.337] 0.406 1.608 [0.500–5.166] 0.425
Systolic pressure (mmHg) 0.985 [0.960–1.011 0.253 0.984 [0.958–1.011] 0.247 0.984 [0.957–1.012] 0.261
O2 Saturation (%) 1.069 [0.986–1.160] 0.107 1.076 [0.992–1.167] 0.079 1.082 [0.993–1.180] 0.071
Bilateral pulmonary infiltrate 2.343 [0.469–11.707] 0.300 3.088 [0.566–16.852] 0.193 3.064 [0.539–17.430] 0.207
Glucose (mg/dl) 1.008 [1.001–1.015] 0.028 1.007 [1.000–1.015] 0.061 1.007 [0.999–1.014] 0.070
INR 1.123 [0.433–2.915] 0.812 1.245 [0.469–3.305] 0.661 1.377 [0.519–3.657] 0.521
D‑dimer (pg/mL) 1.000 [1.000–1.000] 0.294 1.000 [1.000–1.000] 0.190 1.000 [1.000–1.000] 0.420
LDH (UI/L) 1.009 [1.004–1.014] 0.000 1.008 [1.003–1.013] 0.002 1.009 [1.004–1.014] 0.001
GPT (UI/L) 1.005 [0.992–1.019] 0.443 1.005 [0.991–1.019] 0.516 1.006 [0.992–1.021] 0.402
Ferritin (pg/mL) 1.000 [1.000–1.000] 0.705 1.000 [1.000–1.000] 0.856 1.000 [1.000–1.000] 0.835
CRP (mg/dl) 0.998 [0.992–1.003] 0.420 0.999 [0.993–1.005] 0.749 0.998 [0.993–1.004] 0.547
Haematocrit (%) 0.770 [0.676–0.877] 0.000 0.762 [0.665–0.872] 0.000 0.737 [0.633–0.858] 0.000
SARS‑CoV‑2 IgG (Yes) 1.967 [0.627 ‑6.170] 0.246 1.835 [0.562–5.987] 0.315 1.918 [0.577–6.377] 0.288
Lymphocytes (cells/mm3) 0.998 [0.996–1.000] 0.011 0.998 [0.996–1.000] 0.012 0.998 [0.996–0.999] 0.010
Monocytes (cells/mm3) 0.998 [0.995–1.001] 0.180 0.998 [0.995–1.001] 0.212 0.999 [0.996–1.002] 0.463
Neutrophils (cells/mm3) 1.000 [1.000–1.000] 0.262 1.000 [1.000–1.000] 0.326 1.000 [1.000–1.000] 0.239
Viral RNAemia (Yes) 3.916 [1.183–12.968] 0.025 – – – –
Viral RNA load (N1)
in plasma, log (copies/mL)
– – 1.962 [1.244–3.096] 0.004 – –
Viral RNA load (N2)
in plasma, log (copies/mL)
– – – – 2.229 [1.382–3.595] 0.001
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and critical illness suggests that viral replication is more 
robust in severe COVID-19, and/or that critically ill 
patients with this disease are not able to control viral 
replication. This notion is further supported by the cor-
relations found in our study between viral RNA load in 
plasma and hypercytokinemia involving CXCL10, IL-10, 
CCL2, IL-6 and IL-15, where the levels of these cytokines 
were the highest in patients with critical illness. The cor-
relation between viral RNA load and higher levels of 
cytokines has also been described in the severe infections 
caused by H5N1 and pandemic H1N1 influenza strains 
[24] [25]. Active viral replication stimulates the secretion 
of cytokines by the recognition of viral RNA by endo-
somal receptors such as toll like receptor 7 (TLR7) in 
human plasmacytoid dendritic cells and B cells, or TLR8 
in myeloid cells [26]. While the elevation of CXCL10, 
IL-10, CCL2, IL-6 has been extensively documented in 
severe COVID-19 [9, 10], our work demonstrates a clear 
correlation between these cytokines and plasma viral 
load. Furthermore, we report for the first time a major 
role of IL-15 in severe COVID-19. High levels of IL-15 
in critically ill patients with high SARS-CoV-2 RNA load 
in plasma could be an attempt to stimulate Natural Killer 
cells to fight the virus [27]. We previously demonstrated 
that high levels of IL-15, along with IL-6, constituted a 
signature of critical illness in H1N1 pandemic influenza 
infection [20].
Viral RNA load correlated with higher levels of mye-
loperoxidase in plasma, which were the highest in those 
patients admitted to the ICU. This is a marker of neu-
trophil degranulation and a potent tissue damage factor 
which has been proposed to play a role in the pathogen-
esis of ARDS secondary to influenza, by mediating clau-
din alteration on endothelial tight junctions, eventually 
leading to protein leakage and viral spread [28]. In this 
regard, the correlation found between viral RNA load in 
plasma and higher levels of LDH and GPT could suggest 
a direct or indirect role of viral replication in mediating 
tissue destruction in COVID-19.
Interesting, but less robust, direct correlations were 
found between viral RNA load in plasma with GM-CSF 
and neutrophil counts in blood, further reinforcing the 
Fig. 2 Heat map representing the Spearman correlation coefficients between viral RNA load in plasma targeting the N1 and the N2 regions and 
representative indicators of host dysregulated response
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role of neutrophil mediated responses in the pathogen-
esis of severe COVID-19. The direct correlation with 
soluble PDL-1 is also relevant, since this is the ligand of 
the inhibitory co-receptor PD1 on T cells, which activa-
tion induces anergy of T lymphocytes [29]. This finding 
reinforces the potential role of immune checkpoint inhib-
itors in severe COVID-19 [30]. In turn, the associa-
tion found between viral RNA load in plasma and three 
mediators of endothelial dysfunction (VCAM-1, angi-
opoietin-2 and ICAM-1), and with coagulation activation 
Fig. 3 Levels of laboratory parameters indicating host dysregulated response across groups. † indicates significant difference with the healthy 
control and the bars significant differences between the other groups
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markers (D-dimers and INR prolongation) suggests a 
potential virally linked mechanism in the pathogenesis 
of endotheliitis and thrombosis in COVID-19 disease 
[7]. Finally, the correlation with the acute phase reactants 
CRP and ferritin suggests a connection between shed-
ding of genomic material of the virus to the blood and the 
induction of a systemic inflammatory response which is 
observed in those patients needing critical care.
The strongest inverse correlations found in our study 
were between SARS-CoV-2 RNA load in plasma and 
lymphocyte and monocyte counts in peripheral blood, 
for which critically ill patients showed the lowest values. 
Fig. 4 Levels of laboratory parameters indicating host dysregulated response across groups. † indicates significant difference with the healthy 
control and the bars significant differences between the other groups
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Active viral replication could be a precipitating event in 
the pathogenesis of lymphopenia and monocytopenia in 
severe COVID-19 patients [11, 31], by mediating direct 
cytopathic actions or stimulating the migration of these 
cells to the extravascular space to reach the infected tis-
sues [32].
A limitation of our work is its observational nature, 
which precludes to infer causality. Nonetheless, the 
observed associations could serve as hypothesis gen-
erators, leading to the development of animal models to 
confirm the potential link between SARS-CoV-2 repli-
cation and the dysregulated host responses observed in 
severe COVID-19.
Conclusion
The presence of SARS-CoV-2 RNA in plasma is associ-
ated with critical illness in patients with COVID-19. The 
strength of this association increases with viral RNA load 
in plasma, which in turn correlates with key signatures 
of dysregulated host response in COVID-19 (Fig. 5). Our 
findings suggest a major role of uncontrolled viral repli-
cation in the pathogenesis of this disease. Assessment 
of viral RNAemia and viral RNA load in plasma could 
be useful to early detect those patients at risk of clinical 
deterioration, to assess response to treatment and to pre-
dict disease outcome.
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